30 Day Trial
30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

Subscribe to see current content

Biomet Fiscal 2Q12 Results

At press time, only Biomet has reported its next round of quarterly financials. The company’s year-over-year growth appears in Exhibit 2, and performance highlights follow.   Exhib...

Final 3Q11 Results: TiGenix

TIGENIX €0.6MM (~US $0.8MM) • ChondroCelect ~$0.4MM • >40% of ChondroCelect sales generated in Belgium • 5-year follow-up data from multi-center study ...

Final 3Q11 Results: Medtronic

MEDTRONIC (for 2Q12, ended 10/28/11) $839MM, -3% (U.S. $599MM, -7%; ex-U.S. $240MM, +8%) • Core Spinal $631MM, -3% (U.S. $414MM, -7%; ex-U.S. $217, +6%; Hardware -1%, Balloon kyphopla...

Final 3Q11 Results: Bacterin

BACTERIN $4.0MM, +198% • OsteoSponge 50%-60% of revenue • Received $0.24MM U.S. grant for antimicrobial orthopaedic surgical fixation devices • Signed 4 new pr...

Final 3Q11 Results: China Kanghui

CHINA KANGHUI RMB 80.7MM (~US $12.7MM), +27% (Proprietary products: domestic $0.82MM, +37%, international $0.12MM, -14%) • Trauma ~$7.6MM, +23% • Spine ~$4MM, +34% &bull...

Page Navigation